Completed PHASE3 INTERVENTIONAL 3-arm NCT02935530

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Sponsor: Huazhong University of Science and Technology

Conditions Argatroban Gynecologic Neoplasms Low Molecular Weight Heparin Venous Thromboembolism

Updated 6 times since 2017 Last updated: May 12, 2019 Started: Jan 31, 2016 Primary completion: Aug 31, 2017 Completion: Oct 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Argatroban and Gynecologic Neoplasms and is currently completed. Huazhong University of Science and Technology leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Nov 2018 — Jun 2019 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Nov 2018 [monthly]

Recruiting PHASE3

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Huazhong University of Science and Technology

Data source: Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China